Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + Pertuzumab + Digital Health Tools in First-Line HER2+ Metastatic Breast Cancer
NCT07371585Phase 2Recruiting
- Sponsor
- SOLTI
- Start
- Feb 2026
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by SOLTI. Started Feb 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07371585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371585.